First-of-its-kind cancer vaccine raises hope for patients

An experimental cancer vaccine developed by pharmaceutical companies Merck and Moderna has reduced the risk of melanoma recurrence by 42 percent, raising hopes for breakthroughs in cancer treatment.

According to The New York Times, the companies announced Thursday that patients receiving the personalised mRNA vaccine alongside immunotherapy were significantly less likely to experience cancer recurrence within two years.

The clinical trial involved 1,137 melanoma patients, with approximately two-thirds receiving the vaccine alongside pembrolizumab, an immunotherapy drug.

Scientists say the vaccine trains the immune system to recognise and attack cancer cells, potentially preventing the disease from returning.

“This is the first step,” said Dr. Robert Vonderheide, president-elect of the American Association for Cancer Research. “Will it work in other tumors? I’m hopeful. Do we have a lot to learn? For sure.”

Researchers are investigating similar vaccines for pancreatic, brain, kidney and lung cancers.

However, scientists caution that further studies are necessary to establish long-term effectiveness and survival benefits.